Association of chronic fatigue syndrome with premature telomere attrition.
Rajeevan, Mangalathu S, Murray, Janna, Oakley, Lisa et al. · Journal of translational medicine · 2018 · DOI
Quick Summary
This study compared telomere length—the protective caps at the ends of our DNA—between people with ME/CFS and healthy controls. Researchers found that people with ME/CFS had shorter telomeres, suggesting their cells may be aging faster than expected. The effect was strongest in women under 45 years old with ME/CFS, who showed signs of aging equivalent to 10-20 years beyond their actual age.
Why It Matters
This research provides biological evidence that ME/CFS may involve accelerated cellular aging, which could help explain the profound fatigue and symptom severity patients experience. Understanding whether and how ME/CFS accelerates aging could guide future therapeutic strategies and validate the serious physiological nature of the condition.
Observed Findings
ME/CFS patients had telomeres shorter by approximately 635 base pairs compared to non-fatigued controls, corresponding to 10.1-20.5 years of additional cellular aging.
Participants with insufficient fatigue/symptoms (ISF) also showed significantly shortened telomeres (254 base pairs shorter), suggesting a dose-response relationship.
The association between ME/CFS and short telomeres remained statistically significant even after controlling for age, sex, BMI, waist-hip ratio, post-exertional malaise, and education.
Female participants under 45 years old showed the strongest association between ME/CFS and telomere shortening.
Inferred Conclusions
ME/CFS is associated with premature telomere attrition, supporting the hypothesis that the condition involves accelerated aging at the cellular level.
The accelerated aging phenotype in ME/CFS is particularly pronounced in younger women, suggesting potential sex and age-dependent mechanisms.
ME/CFS may warrant inclusion among conditions characterized by accelerated aging, such as diabetes, cardiovascular disease, and other conditions of premature cellular senescence.
Remaining Questions
Does telomere shortening cause ME/CFS symptoms or is it a consequence of the disease process; what is the direction of causality?
What specific biological mechanisms drive the accelerated telomere attrition in ME/CFS, and why is the effect most pronounced in younger women?
What This Study Does Not Prove
This cross-sectional study cannot establish causation or determine whether telomere shortening causes ME/CFS symptoms or results from them. The study does not prove that the accelerated aging process is functionally significant or explains the mechanisms underlying ME/CFS pathology. Results may not generalize to all populations, as the effect was predominantly observed in young women.
What are the functional consequences of shortened telomeres in ME/CFS patients—do shorter telomeres correlate with symptom severity, disease duration, or specific ME/CFS phenotypes?
Could telomere length be developed as a biomarker for disease severity, prognosis, or response to future therapeutic interventions?